By constructing novel CD19 CAR-tTRII-I7R-T cells, which convert the TGF-β signaling into immune-activating IL-7 signaling, the tumor-killing efficacy of modified CAR-T cells was significantly better than in the control group (157). The gene discussed is TGFB1; the disease is neoplasm.